ZFIN ID: ZDB-FISH-150901-14755
Fish name: s843Tg
Genotype: s843Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by s843Tg
Human Disease Conditions Citations
cancer cancer xenotransplantation Ahn et al., 2015
cancer xenotransplantation Yang et al., 2017
cancer xenotransplantation Deng et al., 2015
cancer xenotransplantation Chiavacci et al., 2015
cancer xenotransplantation, chemical treatment: dexamethasone Kanada et al., 2014
bacterial infectious disease bacterial treatment by injection: Mycobacterium marinum M Torraca et al., 2017
glioblastoma multiforme cancer xenotransplantation Zeng et al., 2017
type 2 diabetes mellitus chemical treatment by environment: D-glucose Carnovali et al., 2016
GENE EXPRESSION
Gene expression in s843Tg
RNA expression
Expressed Gene Structure Conditions Figures
alcama standard conditions 12 figures with image from 5 publications
chemical treatment: semaxanib Fig. 4 with image from Sakaguchi et al., 2008
arcn1a standard conditions Fig. 9 from Chen et al., 2017
arcn1b standard conditions Fig. 9 from Chen et al., 2017
atoh8 standard conditions Fig. 3 with image from Place et al., 2017
chemical treatment: vascular endothelial growth factor receptor antagonist Fig. 3 with image from Place et al., 2017
avp standard conditions Fig. 2 with image from Choi et al., 2016
badb standard conditions Fig. 9 from Chen et al., 2017
baxb standard conditions Fig. 9 from Chen et al., 2017
bcl2a standard conditions Fig. 9 from Chen et al., 2017
bglap chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
birc2 standard conditions Fig. 2Fig. S3 from Santoro et al., 2007
cdh5 standard conditions Fig. 3 from Chen et al., 2017
Fig. 2 with image from Xu et al., 2017
Fig. S9 from Kleaveland et al., 2009
cldn15lb standard conditions Fig. 2 with image from Cheung et al., 2012
copa standard conditions Fig. 9 from Chen et al., 2017
copg2 standard conditions Fig. 9 from Chen et al., 2017
crestin standard conditions Fig. 2 with image from Leigh et al., 2013
crip2 standard conditions Fig. 1 from Kim et al., 2014
csf1a standard conditions Fig. 5 from Mahony et al., 2016
csf1b standard conditions Fig. 5 from Mahony et al., 2016
csf3a standard conditions Fig. 5 from Mahony et al., 2016
csf3b standard conditions Fig. 5 from Mahony et al., 2016
cxcl11.1 bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
cxcl12a bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
cxcl18b bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
cxxc5a control Fig. 5 from Kim et al., 2014
ddit3 standard conditions Fig. 9 from Chen et al., 2017
epoa standard conditions Fig. 5 from Mahony et al., 2016
fgfr1a control Fig. 1 with image from De Smet et al., 2014
fgfr2 control Fig. 1 with image from De Smet et al., 2014
fgfr3 control Fig. 1 with image from De Smet et al., 2014
fgfr4 control Fig. 1 with image from De Smet et al., 2014
flt1 control Fig. 3 from Wang et al., 2016
fn1a standard conditions Fig. 1 with imageFig. 3 with imageFig. 5 with imageFig. 6 with imageFig. 8 with image from Chiu et al., 2012
gbf1 standard conditions Fig. 3 from Chen et al., 2017
gnrh3 standard conditions Fig. 2 with image from Choi et al., 2016
hcrt standard conditions Fig. 2 with image from Choi et al., 2016
il1b bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
kdrl standard conditions Fig. 5 from Duong et al., 2014
Fig. S6 from Cermenati et al., 2008
Fig. 1 with image from Jin et al., 2005
kitlgb standard conditions Fig. 5 from Mahony et al., 2016
klf2a control Fig. S12 from Wang et al., 2013
lcp1 standard conditions Fig. 6 from Bukrinsky et al., 2009
lmo2 standard conditions Fig. 3 with image from Weiss et al., 2012
mib1 standard conditions Fig. S4 from Wang et al., 2016
mir10a standard conditions Fig. S1 from Wang et al., 2016
mir138 standard conditions Fig. 1 with image from Morton et al., 2008
mmp9 bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
mmp17a standard conditions Fig. 2 with image from Leigh et al., 2013
mmp17b standard conditions Fig. 2 with imageFig. 4 with image from Leigh et al., 2013
mpx standard conditions Fig. 6 from Bukrinsky et al., 2009
nrg1 standard conditions Fig. 1 with image from Samsa et al., 2016
oxt standard conditions Fig. 2 with image from Choi et al., 2016
podxl2 standard conditions Fig. 4 with image from Herwig et al., 2011
reck standard conditions Fig. 4 with image from Leigh et al., 2013
robo1 control Fig. 3 with image from Fish et al., 2011
sema3d standard conditions Fig. 2 with image from Hamm et al., 2016
sox11b standard conditions Fig. 3 from Schmitt et al., 2013
tfec standard conditions Fig. 1 from Mahony et al., 2016
thpo standard conditions Fig. 5 from Mahony et al., 2016
tnfa bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
tnfrsf1b chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
tnfrsf11b chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
tnfrsf21 control Fig. S3 with image from Tam et al., 2012
tnfsf11 chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
vegfaa bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab1-tagln standard conditions Fig. 3 with imageFig. 5 with imageFig. 6 with imageFig. 7 with imageFig. S2 with image from Santoro et al., 2009
Ab2-slc2a1 control Fig. S3 with imageFig. S5 with image from Tam et al., 2012
Ab1-lrp1 control Fig. 5 from Pi et al., 2012
Ab2-tjp1 standard conditions Fig. S1 with image from Xie et al., 2010
Ab1-cldn5 chemical treatment: bradykinin Fig. 6 with image from Xie et al., 2010
AB1-Ntcp standard conditions Fig. 3 with image from Sakaguchi et al., 2008
Ab1-tjp1 chemical treatment by environment: miconazole Fig. 3 with image from Yang et al., 2017
Ab1-cldn5 standard conditions Fig. 2 with imageFig. 3 with imageFig. 6 with image from Xie et al., 2010
Ab5-tjp1a standard conditions Fig. 7, S2 with image from Fadeev et al., 2015
Ab9-mapk standard conditions Fig. 1 with imageFig. 5 with image from De Angelis et al., 2017
Fig. 4 from Krispin et al., 2017
Ab-CS-56 standard conditions Fig. 3 with image from Peal et al., 2009
Ab3-prox1 standard conditions Fig. 1 with imageFig. 2 with imageFig. 3 with imageFig. 5 with image from Sakaguchi et al., 2008
Ab3-prox1 chemical treatment: semaxanib Fig. 4 with image from Sakaguchi et al., 2008
Ab1-tjp1 standard conditions Fig. 3 with image from Yang et al., 2017
Fig. S3 with image from Yoruk et al., 2012
Fig. 3 from Li et al., 2010
Ab2-fn standard conditions Fig. 10 with image from Mana et al., 2016
Fig. 3 with image from Chou et al., 2013
Ab1-eng standard conditions Fig. 2 with image from Leigh et al., 2013
Ab1-BrdU chemical treatment: 5-bromo-2'-deoxyuridine Fig. 2 from Herzog et al., 2009
Ab1-smad standard conditions Fig. 3 with image from Lenhart et al., 2013
Fig. 5 from Pi et al., 2012
zn-5 alcama standard conditions Fig. 4 from Shin et al., 2014
Fig. 3 with image from Schaub et al., 2012
Fig. 1 with imageFig. 2 with imageFig. 3 with imageFig. 5 with image from Sakaguchi et al., 2008
zn-8 standard conditions Fig. 3 with image from Donat et al., 2018
Fig. 2 with imageFig. 4 with image from Renz et al., 2015
Fig. 4 with imageFig. 6 with image from Patra et al., 2011
zn-5 chemical treatment: semaxanib Fig. 4 with image from Sakaguchi et al., 2008
Ab1-cdh5 cdh5 standard conditions Fig. 2 with image from Xu et al., 2017
Fig. 3 from Li et al., 2010
Fig. S9 from Kleaveland et al., 2009
Ab1-podxl2 podxl2 standard conditions Fig. 4 with image from Herwig et al., 2011
Ab1-sema3d sema3d standard conditions Fig. 2 with image from Hamm et al., 2016
Ab1-tnfrsf21 tnfrsf21 control Fig. S3 with image from Tam et al., 2012
Ab2-tnfrsf21 control Fig. S3 with image from Tam et al., 2012
Reporter gene expression
Expressed Gene Structure Conditions Figures
EGFP standard conditions 191 figures with image from 106 publications
chemical treatment: vatalanib 25 figures with image from 22 publications
cancer xenotransplantation 20 figures with image from 12 publications
GFP standard conditions Fig. 2 with imageFig. 4 with imageFig. 6 with image from Renz et al., 2015
Fig. 3 from Weber et al., 2014
Fig. 3 with imageFig. S1 with image from Cameron et al., 2012
PHENOTYPE
Phenotype in s843Tg
Phenotype Conditions Figures
adrenal gland development process quality, abnormal chemical treatment: pharmaceutical Fig. 2 with image from Chou et al., 2014
adrenal gland development process quality, abnormal chemical treatment: pharmaceutical Fig. 2 with image from Chou et al., 2014
aortic arch diameter, normal chemical treatment: semaxanib Fig. 2 from Herzog et al., 2009
atrioventricular canal endocardium morphology, normal control Fig. 2 from Chen et al., 2013
atrioventricular canal endocardium cell normal amount, normal control Fig. 2 from Chen et al., 2013
atrioventricular valve development process quality, normal control Fig. 2 from Chen et al., 2013
blood glucose increased amount, abnormal chemical treatment by environment: D-glucose Fig. 1 from Carnovali et al., 2016
blood island atoh8 expression decreased distribution, abnormal chemical treatment: bone morphogenetic protein receptor antagonist Fig. 3 with image from Place et al., 2017
blood vessel endothelial cell normal amount, normal standard conditions Fig. 3 from Jin et al., 2017
caudal vein plexus morphology, normal chemical treatment: DAPT Fig. 3 from Chappell et al., 2013
central artery decreased amount, abnormal chemical treatment: IWR-1-endo Fig. 3 with image from Vanhollebeke et al., 2015
central artery increased amount, abnormal chemical treatment: DAPT Fig. 2 with image from Bussmann et al., 2011
dorsal aorta endothelial cell ab9-mapk labeling decreased amount, abnormal standard conditions Fig. 5 with image from De Angelis et al., 2017
dorsal aorta endothelial cell ab9-mapk labeling decreased distribution, abnormal standard conditions Fig. 5 with image from De Angelis et al., 2017
dorsal longitudinal anastomotic vessel malformed, abnormal chemical treatment: semaxanib Fig. 7 from Hassel et al., 2012
female organism decreased life span, abnormal chemical treatment by environment: D-glucose Fig. 1 from Carnovali et al., 2016
granuloma formation decreased occurrence, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 3 with image from Torraca et al., 2017
heart morphology, normal standard conditions Fig. 4 from Chi et al., 2008
heart contraction decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 2 with imageFig. 3 with image from Chou et al., 2014
heart contraction increased rate, abnormal chemical treatment: pharmaceutical Fig. 2 with imageFig. 3 with image from Chou et al., 2014
interrenal angiogenic sprout decreased length, abnormal chemical treatment: pharmaceutical Fig. 3 with image from Chou et al., 2014
interrenal angiogenic sprout increased length, abnormal chemical treatment: pharmaceutical Fig. 3 with image from Chou et al., 2014
interrenal gland animal organ morphogenesis process quality, abnormal chemical treatment: pharmaceutical Fig. 2 with image from Chou et al., 2014
interrenal gland animal organ morphogenesis process quality, abnormal chemical treatment: pharmaceutical Fig. 2 with image from Chou et al., 2014
intersegmental vessel decreased amount, abnormal chemical treatment by environment: semaxanib Fig. 6 with image from De Angelis et al., 2017
intersegmental vessel has fewer parts of type cell, abnormal chemical treatment: semaxanib Fig. 7 from Hassel et al., 2012
intersegmental vessel increased branchiness, abnormal chemical treatment by environment: DAPT Fig. 7 with image from Zhou et al., 2015
intersegmental vessel increased branchiness, abnormal chemical treatment by environment: DAPT Fig. 7 from Wang et al., 2016
intersegmental vessel malformed, abnormal chemical treatment: semaxanib Fig. 7 from Hassel et al., 2012
intersegmental vessel morphology, abnormal chemical treatment by diet: sunitinib Fig. 4 from Kanada et al., 2014
intersegmental vessel morphology, abnormal chemical treatment: DAPT Fig. 3Fig. 5 from Chappell et al., 2013
intersegmental vessel angiogenesis increased process quality, abnormal chemical treatment by environment: DAPT Fig. 7 with image from Zhou et al., 2015
intersegmental vessel angiogenesis process quality, abnormal chemical treatment: DAPT Fig. 3Fig. 5 from Chappell et al., 2013
intersegmental vessel angiogenic sprout amount, normal bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
intersegmental vessel angiogenic sprout decreased amount, abnormal bacterial treatment by injection: Mycobacterium marinum M, chemical treatment by environment: sunitinib Fig. 4 with image from Torraca et al., 2017
intersegmental vessel cell migration involved in sprouting angiogenesis arrested, abnormal chemical treatment: semaxanib Fig. 7 from Hassel et al., 2012
liver morphology, normal standard conditions Fig. 5 with image from Sakaguchi et al., 2008
male organism decreased life span, abnormal chemical treatment by environment: D-glucose Fig. 1 from Carnovali et al., 2016
pharyngeal vasculature decreased width, abnormal chemical treatment: vatalanib Fig. S9 with image from Fish et al., 2008
pharyngeal vasculature disorganized, abnormal chemical treatment: DAPT Fig. 3 from Porazzi et al., 2012
regenerating fin vasculature development decreased process quality, abnormal amputation: caudal fin, chemical treatment: IWR-1-endo Fig. 6 from Li et al., 2014
retina blood vessel broken, abnormal chemical treatment by environment: D-glucose Fig. 2 from Carnovali et al., 2016
retina blood vessel fragile, abnormal chemical treatment by environment: D-glucose Fig. 2 from Carnovali et al., 2016
retina blood vessel increased thickness, abnormal chemical treatment by environment: D-glucose Fig. 2 from Carnovali et al., 2016
retina blood vessel shape, abnormal chemical treatment by environment: D-glucose Fig. 2 from Carnovali et al., 2016
scale bglap expression decreased amount, abnormal chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
scale tnfsf11 expression decreased amount, abnormal chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
scale tnfrsf11b expression decreased amount, abnormal chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
scale decreased area, abnormal chemical treatment by environment: D-glucose Fig. 3 from Carnovali et al., 2016
scale morphology, abnormal chemical treatment by environment: D-glucose Fig. 3 from Carnovali et al., 2016
scale bone remodeling process quality, abnormal chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
scale bone resorption increased occurrence, abnormal chemical treatment by environment: D-glucose Fig. 3Fig. 4 from Carnovali et al., 2016
scale ossification involved in bone remodeling decreased occurrence, abnormal chemical treatment by environment: D-glucose Fig. 4 from Carnovali et al., 2016
sprouting angiogenesis increased occurrence, abnormal chemical treatment: DAPT Fig. 2 with image from Bussmann et al., 2011
subintestinal vein decreased length, abnormal chemical treatment: IWR-1-endo Fig. 5 from Li et al., 2014
subintestinal vein morphology, abnormal chemical treatment: IWR-1-endo Fig. 5 from Li et al., 2014
thyroid gland development decreased process quality, abnormal chemical treatment: DAPT Fig. 3 from Porazzi et al., 2012
thyroid primordium malformed, abnormal chemical treatment: DAPT Fig. 3 from Porazzi et al., 2012
trunk curved, abnormal chemical treatment: DAPT Fig. 5 from Ethell et al., 2014
trunk vasculature morphology, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 1 with imageFig. 2 with imageFig. 3 with imageFig. 4 with image from Torraca et al., 2017
trunk vasculature morphology, ameliorated bacterial treatment by injection: Mycobacterium marinum M, chemical treatment by environment: sunitinib Fig. 4 with image from Torraca et al., 2017
trunk vasculature response to bacterium process quality, abnormal bacterial treatment by injection: Mycobacterium marinum M, chemical treatment by environment: sunitinib Fig. 4 with image from Torraca et al., 2017
vasculature agenesis, abnormal chemical treatment by injection: methoxypoly(ethylene glycol), chemical treatment by injection: poly(caprolactone) polymer, chemical treatment by injection: curcumin Fig. 8 from Gou et al., 2011
vasculature agenesis, abnormal chemical treatment by injection: curcumin Fig. 8 from Gou et al., 2011
vasculature morphology, abnormal chemical treatment by injection: methoxypoly(ethylene glycol), chemical treatment by injection: poly(caprolactone) polymer, chemical treatment by injection: curcumin Fig. 8 from Gou et al., 2011
vasculature morphology, abnormal chemical treatment by injection: curcumin Fig. 8 from Gou et al., 2011
ventral wall of dorsal aorta cell population proliferation decreased process quality, abnormal chemical treatment: NS-398 Fig. 5 with image from Esain et al., 2015
ventral wall of dorsal aorta cell population proliferation increased process quality, abnormal chemical treatment: cannabinoid receptor agonist Fig. 5 with image from Esain et al., 2015
vertebral artery absent, abnormal chemical treatment by environment: sunitinib Fig. 3 with image from Matsuoka et al., 2017
vertebral artery absent, abnormal chemical treatment by environment: vascular endothelial growth factor receptor antagonist Fig. 3 with image from Matsuoka et al., 2017
vertebral artery absent, abnormal chemical treatment by environment: LY294002 Fig. 3 with image from Matsuoka et al., 2017
whole organism decreased size, abnormal chemical treatment: DAPT Fig. 5 from Ethell et al., 2014
whole organism cxcl11.1 expression increased amount, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
whole organism vegfaa expression increased amount, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
whole organism mmp9 expression increased amount, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
whole organism cxcl18b expression increased amount, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
whole organism il1b expression increased amount, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
whole organism cxcl12a expression increased amount, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
whole organism tnfa expression increased amount, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 4 with image from Torraca et al., 2017
whole organism neoplasm decreased size, ameliorated chemical treatment by injection: gold nanoparticle, chemical treatment by injection: doxorubicin, cancer xenotransplantation Fig. 4 from Ahn et al., 2015

CITATIONS  (259)